SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.8x
Market Cap
$70.46M
MomentumView details →
1D Return
−0.82%
YTD Return
−48.28%
RSI (14)
37.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.8x
Market Cap
$70.46M
RSI (14)
37.9
MomentumView details →
1D Return
−0.82%
YTD Return
−48.28%
SummaryUpdated Jun 1, 2026
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in November 2017 and focuses on developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Spero has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline (GSK), Pfizer, and Everest Medicines to advance its pipeline of antibiotic candidates through clinical development and potential commercialization.
Similar companies
Latest newsMore news →
Spero Therapeutics, Inc. terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., effective August 28, 2026, with no shares sold under the agreement in fiscal years 2024 and 2025.7d agoSpero Therapeutics, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell shares of its common stock at-the-market, with a maximum aggregate offering price of $100 million.7d agoSpero Therapeutics received FDA approval for Utebzi, a product for immune-mediated diseases.23d ago